1 results
Approved WMORecruiting
This study has been transitioned to CTIS with ID 2023-503826-37-00 check the CTIS register for the current data. To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and pertuzumab as maintenance therapy in subjects with…